only search Keymodule website

SPROUT User Publications

The First Small-Molecule Inhibitors of Members of the Ribonuclease E Family
Louise Kime, Helen A. Vincent, Deena M. A. Gendoo, Stefanie S. Jourdan, Colin W. G. Fishwick, Anastasia J. Callaghan, Kenneth J. McDowall
Scientific Reports
2015, 5, pp 8028-8028
In Silico Design and Biological Evaluation of a Dual Specificity Kinase Inhibitor Targeting Cell Cycle Progression and Angiogenesis
Antony M. Latham, Jayakanth Kankanala, Gareth W. Fearnley, Matthew C. Gage, Mark T. Kearney, Shervanthi Homer-Vanniasinkam, Stephen B. Wheatcroft, Colin W. G. Fishwick, Sreenivasan Ponnambalam
PLoS ONE
2014, 9
Molecular mechanism of ligand recognition by membrane transport protein, Mhp1
Katie J. Simmons, Scott M. Jackson, Florian Brueckner, Simon G. Patching, Oliver Beckstein, Ekaterina Ivanova, Tian Geng, Simone Weyand, David Drew, Joseph Lanigan, David J. Sharples, Mark S.P. Sansom, So Iwata, Colin W.G. Fishwick, A. Peter Johnson, Alexander D. Cameron, Peter J.F. Henderson
The EMBO Journal
2014, 33, pp 1831-1844
Applications of structure-based design to antibacterial drug discovery
R. Cain, S. Narramore, M. McPhillie, K. Simmons, C.W.G. Fishwick
Bioorg. Chem.
2014, 55, pp 69-74
Assay Platform for Clinically Relevant Metallo--lactamases
Sander S. van Berkel, Jurgen Brem, Anna M. Rydzik, Ramya Salimraj, Ricky Cain, Anil Verma, Raymond J. Owens, Colin W. G. Fishwick, James Spencer, Christopher J. Schofield
J. Med. Chem.
2013, 56(17), pp 6945-6953
Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design
N.Y. Mok, J. Chadwick, K.A. Kellett, E. Casas-Arce, N.M. Hooper, A.P. Johnson, C.W. Fishwick
J. Med. Chem.
2013, 56 (5), pp 1843-1852
A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis
J. Kankanala, A.M. Latham, A.P. Johnson, S. Homer-Vanniasinkam, C.W.G. Fishwick, S. Ponnambala
British Journal of Pharmacology
2012, 166 (2), pp 737-748
Structure-based discovery of antibacterial drugs
Katie J. Simmons, Ian Chopra, Colin W. G. Fishwick
Nature Reviews Microbiology
2010, 8 (7), pp 501-510
Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases
Matthew Davies, Timo Heikkila, Glenn A. McConkey, Colin W. G. Fishwick, Mark R. Parsons, A. Peter Johnson
J. Med. Chem.
2009, 52 (9), pp 2683-2693
Design and synthesis of new hydroxyethylamines as inhibitors of D-alanyl-D-lactate ligase (VanA) and D-alanyl-D-alanine ligase (DdlB)
Matej Sova, Gasper Cadez, Samo Turk, Vita Majce, Slovenko Polanc, Sarah Batson, Adrian J. Lloyd, David I. Roper, Colin W. G. Fishwick, Stanislav Gobec
Bioorg. Med. Chem. Lett.
2009, 19 (5), pp 1376-1379
Synthesis of de novo designed small-molecule inhibitors of bacterial RNA polymerase
Anil K. Agarwal, A. Peter Johnson, Colin W. G. Fishwick
Tetrahedron
2008, 64 (43), pp 10049-10054
Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core
Jon J. Hangeland, Daniel L. Cheney, Todd J. Friends, Stephen Swartz, Paul C. Levesque, Adam J. Rich, Lucy Sun, Terry R. Bridal, Leonard P. Adam, Diane E. Normandin, Natesan Murugesan, William R. Ewing
Bioorg. Med. Chem. Lett.
2008, 18 (2), pp 474-478
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase
Timo Heikkila, Christopher Ramsey, Matthew Davies, Christophe Galtier, Andrew M. W. Stead, A. Peter Johnson, Colin W. G. Fishwick, Andrew N. Boa, Glenn A. McConkey
J. Med. Chem.
2007, 50 (2), pp 186-191
The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase
Timo Heikkila, Srinath Thirumalairajan, Matthew Davies, Mark R. Parsons, A. Glenn McConkey, Colin W. G. Fishwick, A. Peter Johnson
Bioorg. Med. Chem. Lett.
2006, 16 (1), pp 88-92
A novel de novo designed inhibitor of D-ala-D-ala ligase from E.coli.
Gilbert E. Besong, Julieanne M. Bostock, Will Stubbings, Ian Chopra, David I. Roper, Adrian J. Lloyd, Colin W. G. Fishwick, A. Peter Johnson
Angew. Chem. Int. Ed. Engl.
2005, 44 (39), pp 6403 - 6406
The first de novo-designed antagonists of the human NK2 receptor
Mohammed A. Ali, Nirmala Bhogal, John B. C. Findlay, Colin W. G. Fishwick
J. Med. Chem.
2005, 48 (18), pp 5655-5658
Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors
Qi Han, Celia Dominguez, Pieter F. W. Stouten, Jeongsook M. Park, Daniel E. Duffy, Robert A. Galemmo, Jr., Karen A. Rossi, Richard S. Alexander, Angela M. Smallwood, Pancras C. Wong, Matthew M. Wright, Joseph M. Luettgen, Robert M. Knabb, Ruth R. Wexler
J. Med. Chem.
2000, 43 (23), pp 4398-4415
Molecular modeling in the discovery of drug leads
George W. A. Milne, Shaomeng Wang, and Marc C. Nicklaus
J. Chem. Inf. Comp. Sci.
1996, 36 (4), pp 726-730